Ulf Grawunder

USPTO Granted Patents = 22 (Patent Applications = 9)

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 7 (Patent Applications = 19)

Average Co-Inventor Count = 2.3

ph-index = 4

Forward Citations = 71(Granted Patents)

Location History:

U.G. Hersberg, CH (2014 - 2019)
Hersberg, CH (2020 - 2023)
Basel, CH (2010 - 2024)

Company Filing History:

The Scripps Research Institute

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275789 - Human antibodies binding to ROR2 (2025-04-14),

2. 12121527 - Anthracycline-based antibody drug conjugates having high in vivo tolerability (2024-10-22),

3. 11986535 - Method of producing an immunoligand/payload conjugate (2024-05-21),

4. 11845793 - Anti-ROR1 antibodies (2023-12-19),

5. 11833120 - Binding protein drug conjugates comprising anthracycline derivatives (2023-12-05),

6. 11447546 - Human antibodies binding to ROR2 (2022-09-20),

7. 11364301 - Method of producing an immunoligand/payload conjugate (2022-06-21),

8. 11242388 - ROR1 antibody compositions and related methods (2022-02-08),

9. 10960083 - Binding protein drug conjugates comprising anthracycline derivatives (2021-03-30),

10. 10864277 - Method of producing an immunoligand/payload conjugate (2020-12-15),

11. 10758556 - Anthracycline-based antibody drug conjugates having high in vivo tolerability (2020-09-01),

12. 10618959 - ROR1 antibody compositions and related methods (2020-04-14),

13. 10517959 - Binding protein drug conjugates comprising anthracycline derivatives (2019-12-31),

14. 10502745 - Identification of antigen- or ligand-specific binding proteins (2019-12-10),

15. 10188745 - Binding protein drug conjugates comprising anthracycline derivatives (2019-01-29),

Title: The Innovator Ulf Grawunder: Pioneering Advances in Antibody Drug Conjugates

Introduction: Ulf Grawunder, based in Basel, Switzerland, is a prominent inventor with a strong track record in the field of antibody drug conjugates (ADCs). Throughout his career, he has been awarded 21 patents, showcasing his commitment to innovation in biochemistry and drug development.

Latest Patents: Among his most recent patents is the invention titled "Anthracycline-based antibody drug conjugates having high in vivo tolerability." This cutting-edge technology focuses on improving the properties of ADCs, ensuring they have enhanced tolerability in living organisms, a significant step forward in therapeutic applications. Another noteworthy patent is the "Method of producing an immunoligand/payload conjugate," which details a novel approach to conjugating a payload to an immunoligand using a sequence-specific transpeptidase, or its catalytic domain. These inventions represent Grawunder's dedication to advancing the field of targeted therapies.

Career Highlights: Ulf Grawunder has made significant contributions to the pharmaceutical industry, particularly through his work at NBE-Therapeutics AG and 4-Antibody AG. His experience in these companies has allowed him to pioneer innovative solutions in drug development, focusing on improving cancer therapies and patient outcomes.

Collaborations: Collaborating with esteemed professionals in the field, including Roger Renzo Beerli and Lorenz Waldmeier, Grawunder has strengthened his research through collective expertise. These partnerships have facilitated creative problem-solving and led to impactful advancements in biomedicine.

Conclusion: Ulf Grawunder stands out as a key innovator in the sphere of antibody drug conjugates, with a remarkable portfolio of patents that reflect his passion for scientific progress. His contributions to the pharmaceutical industry through collaborations and innovative methods are paving the way for safer and more effective treatments, underscoring his importance in the field of biochemistry.

This text is generated by artificial intelligence and may not be accurate.